Nimustine
Chemical compound
- L01AD06 (WHO)
- In general: ℞ (Prescription only)
- N'-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-(2-chloroethyl)-N-nitrosourea
- 42471-28-3 Y
- 39214
- 35876 N
- 0S726V972K
- D08276 Y
- CHEBI:75270 N
- DTXSID0045179
- Interactive image
- CC1=NC=C(C(=N1)N)CNC(=O)N(CCCl)N=O
InChI
- InChI=1S/C9H13ClN6O2/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14) N
- Key:VFEDRRNHLBGPNN-UHFFFAOYSA-N N
Nimustine (INNTooltip International Nonproprietary Name) is a nitrosourea alkylating agent.[1]
It is used to treat malignant brain tumors and has proven to be rather effective.[2][3]
References
- ^ "NCI Drug Dictionary". National Cancer Institute. Retrieved 2019-03-17.
- ^ CHEBI:75270 - nimustine
- ^ Endo T, Inoue T, Sugiyama S, Saito R, Tominaga T (April 2020). "Regression of Recurrent Spinal Cord High-Grade Glioma After Convection-Enhanced Delivery of Nimustine Hydrochloride: Case Reports and Literature Review". Operative Neurosurgery (Hagerstown, Md.). 18 (4): 451–459. doi:10.1093/ons/opz172. PMID 31414134.
- v
- t
- e
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e